Clinical Trial: NCT03913949
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Ascentage Pharma Group Inc. |
| Information Provided By: | Ascentage Pharma Group Inc. |
| Last Update Posted: | 2026-05-01 |
Study Overview
Brief Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic lymphocytic leukemia and non-hodgkin's lymphoma.
Official Title
A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Properties of Orally Administered APG-2575 in Patients With Hematologic Malignancies
Conditions
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Intervention / Treatment
- Drug: APG-2575
Other Study ID Numbers
- APG-2575-CN-001
Start Date (Actual)
2019-06-03
Primary Completion Date (Actual)
2024-10-20
Study Completion Date (Estimated)
2026-12-31
Enrollment (Estimated)
74
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Ascentage Pharma Group Inc. |
| Information Provided By: | Ascentage Pharma Group Inc. |
| Last Update Posted: | 2026-05-01 |
Study Overview
Brief Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic lymphocytic leukemia and non-hodgkin's lymphoma.
Official Title
A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Properties of Orally Administered APG-2575 in Patients With Hematologic Malignancies
Conditions
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Intervention / Treatment
- Drug: APG-2575
Other Study ID Numbers
- APG-2575-CN-001
Start Date (Actual)
2019-06-03
Primary Completion Date (Actual)
2024-10-20
Study Completion Date (Estimated)
2026-12-31
Enrollment (Estimated)
74
Study Type
Interventional
Phase
Phase 1